Diabetic nephropathy. A matter of inflamation?;Nefropatía diabética: ¿Una cuestión de inflamación? Hipótesis del daño renal inflamatorio en la diabetes mellitus tipo 2

Nefrologia

Volumn 23, Issue 5, 2003, Pages 381-389

  Navarro, J ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 6; METHYLXANTHINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; QUINAPRIL; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN; AUTACOID;

DIABETIC NEPHROPATHY; EDITORIAL; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; KIDNEY DISEASE; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; METABOLISM; PATHOPHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; INFLAMMATION MEDIATORS; NEPHRITIS;

EID: 1542756291     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (82)

1. Kopelman PG, Hitman GA: Exploding type II. Lancet 352 (Supl. IV): 5, 1998.
2. King H, Aubert RE, Herman WH: Global burden of diabetes: 1995-2005: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414-1431, 1998.
3. De Pablos-Velasco PL, Martínez-Martín FJ, Rodríguez-Pérez F, Ania BJ, Losada A, Betancor P: The Guia Study. Prevalence and determinants of diabetes mellitus and glucose ina Canarian Caucasian population - comparison of the 1997 ADA and the 1985 WHO criteria. The Guia Study. Diabet Med 18: 235-241, 2001.
4. Velázquez JA, Gaztambide S, Soto-Pedre E: Estudio prospectivo de 10 años sobre la incidencia y factores de riesgo de diabetes mellitus tipo 2. Med Clin 115: 534-539, 2000.
5. Zimmet P: Glozalization, coca-colonization and the chronic disease epidemic: can the doomsday scenario be adverted? J Intern Med 247: 301-310, 2000.
6. Centers for Disease Control and Prevention: Diabetes Surveillance, 1997, Atlanta GA, Department of Health and Human Services, 1997.
7. Rabkin R: Diabetic nephropathy. Clin Cornerstone 5: 1-11, 2003.
8. United States Renal Data System: USRDS 1994 annual data report. Bethesda, MD, National Institutes of Diabetes and Digestive and Kidney Diseases, 1997.
9. Pastan S, Bailey J: Dialysis therapy. N Engl J Med 338: 1428-1437, 1998.
10. Zatz R, Dunn BR, Meyer TW, Anderson S, Renke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-130, 1986.
11. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
12. Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352: 213-219, 1988.
13. Marrón B, Ortiz A, Egido J: Factures patogénicos en la nefropatía diabética. ¿De dónde venimos y hacia dónde vamos? Nefrología XXI (Supl. 3): 18-23, 2001.
14. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy R, Haffner S: Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 102: 42-47, 2000.
15. Esposito K, Happo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliano L, Coriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Role of oxidative stress. Circulation 106: 2067-2072, 2002.
16. Chen J, Gall MA, Yokoyama H, Jensen J, Deckert M, Parving HH: Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy. Diabetes Care 19: 130-4, 1996.
17. Nielsen S, Schmitz A, Bacher T, Rehling M, Ingerslev J, Mogensen C: Transcapillary scape rate and albuminuria in type II diabetes. Effects of short-term treatment with low-molecular weight heparin. Diabetología 42: 60-67, 1999.
18. Carr M: Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 15: 44-54, 2001.
19. Rodríguez-Morán M, Guerrero-Romero F: Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. J Diabetes Complications 19: 211-215, 1999.
20. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatami K, Yano Y: Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83: 859-862, 1998.
21. Zinman B, Hanley A, Harris S, Kwan J, Fantus G: Circulating tumor necrosis factor-α concentrations in a native canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 84: 272-278, 1999.
22. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospetive Investigation into Cancer and Nutrition (EPIC)- Postdam Study. Diabetes 52: 812-817, 2003.
23. Pickup J, Chusney G, Thomas S, Burt D: Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67: 291-300, 2000.
24. Kado S, Nagase T, Nagata N: Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol 36: 67-72, 1999.
25. Esposito K, Nappo F, Giugliano F, Di Pablo C, Ciotola M, Barbieri M, Paolisso G, Giugliano D: Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care 26: 1647, 2003.
26. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Griesmader A, Drager R, Muller M: Thrombogenic factors are related to urinary albumin excretion rate in type I (insulin-dependent) and type II (non-insulin-dependent) diabetic patients. Diabetología 36: 1045-1060, 1993.
27. Abdella N, Akanji A, Mojiminiyi O, Al Assoussi A, Moussa M: Relation of serum total sialic acid concentrations with diabetic complications and cardiovascular risk factors in Kuwaiti type 2 diabetic patients. Diabetes Res Clin Pract 50: 65-72, 2000.
28. Howard BV, Lee ET, Cowan LD, Fabsitz R, Howard W, Oopik A, Robbins D, Savage P, Yeh J, Welky T: Coronary heart disease prevalence and its relation to risk factors in American Indians: the Strong Heart Study. Am J Epidemiol 142: 254-256, 1995.
29. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo Perin P: Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 26: 2150-2155, 2003.
30. Navarro JF, Mora C, Macía M, García J: Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis 42: 53-61, 2003.
31. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy R, Haffner S: Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney Int 58: 1703-1710, 2000.
32. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH: Increases urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated and independently associated with risk of death. Diabetes 51: 1157-1165, 2002.
33. Jager A, Van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stenhouwer CD: C-ractive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link to cardiovascular risk. Atheroscler Thromb Vasc Biol 22: 593-598, 2002.
34. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, Kondo M: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40: 1007-1012, 1991.
35. Melcion C, Lachman E, Killen D, Morel-Maroger E, Striker GE: Mesangial cells, effect of monocyte products on proliferation and matrix synthesis. Transplant Proc 14: 559-564, 1982.
36. Pfeilschifer J, Pignat W, Vosbeck K, Märki F: Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. Biochem Biophys Res Commun 159: 385-394, 1989.
37. Royall JA, Berkow RE, Beckman JS, Cunningham MK, Matalon S, Freeman BA: Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 257: L399-L410, 1989.
38. Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspect of interleukin 6. Immunol Today 11: 443-449, 1990.
39. Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde M, Endoh M, Nomoto Y, Sakai H: In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44: 1233-1238, 1995.
40. Cahoon S, Vines A, Saxena U, Pillarisetti S: Synergistic induction of endothelial IL-6 by diabetic stimuli: an initiating event in diabetic nephropathy? Diabetes 50 (Supl. 2): 70, 2001.
41. Sekizuka K, Tomino Y, Sei C, Kurusu A, Tashiro K, Yamaguchi Y, Kodera S, Hishiki T, Shirato I, Koide H: Detection of serum IL-6 in patients with diabetic nephropathy. Nephron 68: 284-285, 1994.
42. Shikano M, Sobajima H, Yoshikawa H, Toba T, Kushimoto H, Katsumata H, Tomita M, Kawashima S: Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 85: 81-85, 2000.
43. DiPetrillo K, Coutermarsh B, Gesek FA: Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284: F113-F121, 2003.
44. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macía M, Méndez ME, García J: Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of petoxifylline administration. Am J Kidney Dis 33: 458-463, 1999.
45. Moriwaki I, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, Hada T: Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabets mellitus: relationship with diabetic nephropathy. Metabolism 52: 605-608, 2003.
46. Noronha IL, Niemir Z, Stein H, Waldherr R: Cytokines and growth factors in renal disease. Nephrol Dial Transplant 10: 775-786, 1995.
47. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomio Y, Koide H: mRNA expression of growth factors in glomeruli of diabetic rats. Diabetes 42: 450-456, 1993.
48. Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H: Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the over expression of tumour necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetología 42: 878-886, 1999.
49. Pober JS, Cotran RS: Effects of cytokines on vascular endothelium: their role in vascular and immune injury. Kidney Int 35: 969-975, 1985.
50. Ostendorf T, Burg M, Floege J: Cytokines and glomerular injury. Kidney Blood Press Res 19: 281-289, 1996.
51. Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, Remuzzi G: Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 134: 419-430, 1989.
52. Ortiz A, Gómez-Chiari M, Alonso J, Serón D, Condom E, González E, Egido J: La participación de citoquinas y matriz extracelular en la progresión del daño renal. Nefrología 12 (Supl. 5): 22-32, 1992.
53. Ortiz A, González-Cuadrado S, Bustos C, Alonso J, Gómez-Guerrero C, López-Armada MJ, González-Arana E, Plaza JJ, Egido J: Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 8: 27-34, 1995.
54. McCarthy E, Sharma R, Sharma M, Li JZ, Ge XL, Dillepan K, Savin V: TNF-α increases albumin permeability of isolated rat glomeruli through the generation of superioxide. J Am Soc Nephrol 9: 433-438, 1998.
55. Mahmud N, O'Connel M, Stinson J, Goggins M, Weir D, Kelleher D: Tumor necrosis factor-alpha and microalbuminuria in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 7: 215-219, 1995.
56. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD: Expressio of advanced glycation and products and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease. J Am Soc Nephrol 11: 1656-1666, 2000.
57. Heidland A, Sebekova K, Schinzel R: Advanced glycation and products and the progressive course of renal disease. Am J Kidney Dis 38 (Supl. 1): 100-106, 2001.
58. Schmidt A, Hori O, Cao R, Yan S, Brett J, Wautier J, Ogawa S, Kuwabara K, Marsumoto M, Stern D: RAGE: a novel cellular receptor for advanced glycation and products. Diabetes 45 (Supl. 3): 77-80, 1996.
59. Abel M, Titthaler U, Zhang Y, Deng Y, Schmidt AM, Greten J, Sernau T, Wahl P, Andrassy K, Ritz E: Expression of receptors for advanced glycation and products in renal disease. Nephrol Dial Transplant 10: 1662-1667, 1995.
60. Vlassara H: Receptor-mediated interactions of advanced glycosylation and products with cellular components within diabetic tissues. Diabetes 41 (Supl. 2): 52-56, 1992.
61. Iglesias J, Levine JS: Albuminuria and renal injury - beware of protein bearing gifts. Nephrol Dial Transplant 16: 215-218, 2001.
62. Zhang SL, To C, Chen X, Filep JG, Tang SS, Ingelfinger JR, Carriere S, Chan JS: Effect of renin-angiotensin system blockade on the expression of the angiotensinogen gene and induction of hypertrophy in rat kidney proximal tubular cells. Exp Nephrol 9: 109-117, 2001.
63. Singh R, Alavi N, Singh AK, Leehey DJ: Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48: 177-184, 1999.
64. Singh R, Singh A, Alavi N, Leehey D: Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 14: 873-880, 2003.
65. Ferreri NR, Escalante BA, Zhao Y, An SJ, McGiff J: Angiotensin II induces TNF production by the thick ascending limb: functional implications. Am J Physiol 274: F148-F155, 1998.
66. Ruiz-Ortega M, Rupérez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 82 (Supl. 2): 12-22, 2002.
67. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, Egido J: Proinflammatory actios of angiotensins. Cuir Opin Nephrol Hypertens 10: 321-329, 2001.
68. Utimura R, Fujihra CK, Mattar AL, Malheiros DM, De Lourdes Noronhaa I, Zatz R: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63: 209-216, 2003.
69. Ward A, Clissold SP: Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50-97, 1987.
70. Loftis LL, Meals EA, English BK: Differential effects of pentoxifylline and interleukin-10 on production of tumor necrosis factor and inducible nitric oxide synthase in murine macrophages. J Infect Dis 175: 1008-1011, 1997.
71. Zeni F, Pain P, Vindimian M, Gay JP, Gery P, Bertrand M, Page Y, Page D, Vermesch R, Bertrand JC: Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, ranclomisd, placebo-controlled study. Crit Care Med 24: 207-214, 1994.
72. Han J, Thompson P, Beutler D: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 172: 393-394, 1990.
73. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA: Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110: 192-198, 1991.
74. Guerrero-Romero F, Rodríguez-Morán M, Paniagua-Sierra J, García-Bulnes G, Salas-Ramírez M, Amato D: Pentoxifylline reduces proteinuria in insulin-dependent and non-dependent diabetic patients. Clin Nephrol 43: 116-121, 1995.
75. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ: Pnetoxifylline attenuated the renal disease progression in rats with remnant kidney. Kidney Int 13: 2916-2929, 2002.
76. Niimi R, Nakamura A, Yaagawa Y: Suppression of endotelin-induced renal tumor necrosis factor-α and interleukin-6 mRNA by renin-angiotensin system inhibitors. Jpn J Pharmacol 88: 139-145, 2002.
77. Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J: Angiotensin II participates in mononuclear cell recruitment in the kidney through nuclear factor-kappa B activation and monocyte chemoattractan protein-1 gene expression. J Immunol 161: 430-439, 1998.
78. Togashi N, Ura N Higashiura K, Murakami H, Shimamoto K: The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 18: 1605-1610, 2000.
79. Siragy HM, Awad A, Abadir P, Webb R: The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats. Endocrinology 144: 2229-2233, 2003.
80. Liu L, Zhao SP: The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Int J Cardiol 69: 77-82, 1999.
81. Gurlek A, Kilickap M, Dincer I, Dandachi R, Tutkak H, Oral D: Effect of losartan on circulating TNF alpha levels and left ventricular systolic performance in patients with heart failure. J Cardiovasc Risk 8: 279-282, 2001.
82. Navalkar S, Parthsarathy S, Santanam N, Khan BV: Irbesartan, and angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 37: 440-444, 2001.